- Home
- RIGL vs SXC Comparison
RIGL vs SXC Comparison
Compare RIGL & SXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | SXC |
|---|---|---|
| Founded | 1996 | 1960 |
| Country | United States | United States |
| Employees | N/A | 848 |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 801.2M |
| IPO Year | 2000 | 2011 |
Fundamental Metrics
Financial Performance| Metric | RIGL | SXC |
|---|---|---|
| Price | $48.73 | $9.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $63.00 | $9.50 |
| AVG Volume (30 Days) | 187.8K | ★ 897.5K |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 4.85% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | 0.10 |
| Revenue | $294,282,000.00 | ★ $1,600,300,000.00 |
| Revenue This Year | $3.89 | $0.68 |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | ★ $37.03 | $98.35 |
| Revenue Growth | ★ 64.15 | 10.30 |
| 52 Week Low | $24.84 | $5.52 |
| 52 Week High | $52.24 | $10.68 |
Technical Indicators
Market Signals| Indicator | RIGL | SXC |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 45.89 |
| Support Level | $44.50 | $9.14 |
| Resistance Level | $50.19 | $9.79 |
| Average True Range (ATR) | 1.83 | 0.28 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 66.42 | 4.81 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.